Could This Biosimilar Drug Candidate Create a Blockbuster for Amgen?

Could This Biosimilar Drug Candidate Create a Blockbuster for Amgen?

J&J's immunology mega-blockbuster loses exclusivity in the U.S. next year -- and Amgen's biosimilar is ready to capitalize.